Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram for quality of life and prevention of depression after mastectomy in breast cancer
IRCT20180421039376N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Escitalopram with Placebo (2 arms). Primary endpoints: Depression score, Anxiety score and 1 more. Started Apr 2018; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20180421039376N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180421039376N1.